备注:
国外库存,货期2-4周,具体详情请联系销售人员。
详细介绍
l 基本信息 |
产品名称 | BAY-X-1005 |
一般描述 | Inhibition of soluble epoxide hydrolase by AUDA inhibits the metabolism of epoxyeicosatrienoic acids (EETs) and protects end-organs against the damaging effects of salt-sensitive hypertension. AUDA also renders protection against myocardial ischemia-reperfusion injury and cerebral ischemia. |
别 称 | DG 031, Velifapon, Veliflapon; α-Cyclopentyl-4-(2-quinolinylmethoxy)-(R)-benzeneacetic acid, (αR)-α-Cyclopentyl-4-(2-quinolinylmethoxy)-benzeneacetic acid |
纯 度 | ≥98.0%(HPLC) | CAS NO. | 128253-31-6 |
分子式 | C23H23NO3 | 分子量 | 361.43 |
适用范围 | 生物试剂,适用于细胞培养等 |
l 理化信息 |
外 观 | 白色至米色固体 |
溶解性(25℃) | DMSO | ~5mg/mL |
l 生物学信息 |
生物活性/药理作用 | Bay-X-1005 is a potent inhibitor of 5-lipoxygenase activating protein (FLAP). Bay-X-1005 inhibits A23187-induced LTB4 production in human leucocytes with an IC50 value of 220 nM, and blocks IgE mediated airway contractions. |
l 存储 |
存储温度 | -20℃ |
l 注意事项及免责声明 |
本产品仅用于实验研究,不得作为药物使用,不得用于家用或其它用途。 |
l 参考文献 |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |